Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’
Also reported by BBC Top Stories
Summary
In a trial of 61 people with advanced pancreatic cancer, the drug daraxonrasib stopped tumours from growing in 90% of patients, while tumours shrank or became undetectable in just over 60%. After one year, 76.6% of participants were alive; researchers say longer studies are needed to learn how long the effects last and whether the drug can produce remission.Key Facts
- Trial participants had pancreatic cancer that had spread to other parts of the body.
- Tumours stopped growing in 90% of the 61 participants.
- Tumours shrank or became undetectable in just over 60% of participants.
- Tumours were undetectable on CT scans in about 8% of participants.
- After one year of treatment, 76.6% of participants were alive.
- Participants were followed for an average of 18 months.
- Daraxonrasib blocks certain KRAS mutations that can drive tumour growth.
- Further studies are needed to assess longer-term effects and possible use in other cancers.
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.